Cantor Fitzgerald initiated coverage on Eli Lilly with a new price target
$LLY
Biotechnology: Pharmaceutical Preparations
Health Care
Cantor Fitzgerald initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $975.00
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/5/2025 | Buy → Hold | Erste Group | |
| 4/28/2025 | $1150.00 → $700.00 | Buy → Reduce | HSBC Securities |
| 4/22/2025 | $975.00 | Overweight | Cantor Fitzgerald |
| 12/10/2024 | $997.00 | Buy | BofA Securities |
| 11/15/2024 | $1000.00 | Outperform | Wolfe Research |
| 10/17/2024 | $1100.00 | Outperform | Bernstein |
| 9/13/2024 | $1060.00 | Buy | Citigroup |
| 8/12/2024 | $1025.00 | Hold → Buy | Deutsche Bank |
For Immediate Release: May 31, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA approved mRESVIA (Respiratory Syncytial Virus Vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. mRESVIA is an mRNA-based vaccine that is manufa
For Immediate Release: May 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, the FDA announced a meeting of the Psychopharmacologic Drugs Advisory Committee on June 4 to discuss a new drug application for midomafetamine (MDMA) capsules, submitted by Lykos Therapeutics, for the treatment of post-traumatic stress disorder. The committ
For Immediate Release: December 05, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency: Today, registration opened for the FDA’s virtual Rare Disease Day on Friday, March 1, 2024. This year’s Rare Disease Day is dedicated to patients and health care professionals. Panels will discuss efforts to address the unique challenges with developing treat